PMC:7594251 / 66858-67804
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T53232 | 155-162 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T29588 | 219-227 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T476 | 27-28 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T477 | 56-57 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T478 | 108-113 | http://purl.obolibrary.org/obo/CLO_0001236 | denotes | (2) a |
| T479 | 165-168 | http://purl.obolibrary.org/obo/CLO_0001294 | denotes | 322 |
| T480 | 306-307 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T481 | 342-345 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T482 | 639-642 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T40024 | 89-95 | Chemical | denotes | ligand | http://purl.obolibrary.org/obo/CHEBI_52214 |
| T61396 | 97-101 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T52516 | 155-162 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T39565 | 219-227 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T23111 | 739-743 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T39289 | 827-831 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T457 | 0-280 | Sentence | denotes | Virtual screening requires a minimum of two inputs, (1) a three-dimensional model of the ligand (drug), and (2) a three-dimensional model of the receptor (protein) [322], the latter generated from the atomic studies of proteins via X-ray crystallography or NMR spectroscopy [323]. |
| T458 | 281-578 | Sentence | denotes | Virtual screening is not a truly “stand-alone” technique and has often been combined with additional biophysical techniques besides NMR spectroscopy and/or X-ray crystallography [324], such as differential scanning fluorimetry [325], fluorescence polarization, and surface plasmon resonance [324]. |
| T459 | 579-751 | Sentence | denotes | In this section, we briefly introduce how virtual screening has been combined with NMR spectroscopy, and how they are complementary approaches to each other in drug design. |
| T460 | 752-946 | Sentence | denotes | The complete details of how virtual screening works, and how it applies to drug design outside of its combination with NMR is well documented in additional reviews [310,322,326,327,328,329,330]. |